We create innovative treatments for nervous system damage due to injury or disease.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
View our Corporate Presentation
Subscribe to our mailing list to stay up to date
November 9, 2023
NervGen reported its financial and operational results for the third quarter ended September 30, 2023.
November 8, 2023
NervGen announced that renowned neuroscientist, Dr. Jerry Silver, inventor of NervGen’s lead drug candidate, NVG-291, and NervGen Scientific Advisor, joined Guy Kawasaki on his acclaimed podcast, “Remarkable People”.
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should